Academic Journal
Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary?
| Τίτλος: | Clinically significant tumor histology in suspected primary bladder cancer: is every transurethral resection necessary? |
|---|---|
| Συγγραφείς: | Leitsmann C; Department of Urology, Medical University of Graz, Graz, Austria., Reese AS; Department of Urology, Medical University of Graz, Graz, Austria., Zigeuner R; Department of Urology, Medical University of Graz, Graz, Austria., Zurl H; Department of Urology, Medical University of Graz, Graz, Austria.; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Pohl K; Department of Urology, Medical University of Graz, Graz, Austria.; Center for Surgery and Public Health, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Mischinger J; Department of Urology, Medical University of Graz, Graz, Austria., Simunovic I; Department of Urology, Medical University of Graz, Graz, Austria., Ketterer C; Department of Urology, Medical University of Graz, Graz, Austria., Koll F; Department of Urology, Medical University of Graz, Graz, Austria., Mannweiler S; Department of Pathology, Medical University of Graz, Graz, Austria., Leitsmann M; Department of Urology, Medical University of Graz, Graz, Austria.; aQua-Institute for Applied Quality Improvement and Research in Health Care, Goettingen, Germany., Ahyai S; Department of Urology, Medical University of Graz, Graz, Austria. |
| Πηγή: | Frontiers in surgery [Front Surg] 2026 Jun 12; Vol. 13, pp. 1813017. Date of Electronic Publication: 2026 Jun 12 (Print Publication: 2026). |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101645127 Publication Model: eCollection Cited Medium: Print ISSN: 2296-875X (Print) Linking ISSN: 2296875X NLM ISO Abbreviation: Front Surg Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Lausanne : Frontiers Media S.A., [2014]- |
| Περίληψη: | Purpose: Transurethral resection of bladder tumor (TURBT) is the standard for diagnosis and initial treatment of non-muscle-invasive bladder cancer (NMIBC) a disease with highly variable presentation. To evaluate the rate of malignancy in patients undergoing elective TURBT for suspected BC. Methods: A retrospective analysis of 217 patients undergoing primary TURBT for BC suspicion at our tertiary care center between January and June 2023 was performed.Key parameters included preoperative macroscopic cystoscopy findings, intraoperative macroscopic findings, and pathologic tumor characteristics from the TURBT specimen. The primary outcome was the detection rate of malignancy. Secondary outcomes included the correlation of the interobserver congruence on preoperative and TURBT findings. Multivariate logistic regression was performed to identify significant predictors of malignancy. Results: Of 217 patients, 35% had no malignancy in the TURBT specimen. Interobserver congruence was observed in 80.6% of cases. Papillary findings in the initial cystoscopy (Odds ratio (OR) = 5.6, 95% Confidence interval (CI) = 2.18-14.52, p < 0.001), age (OR = 1.057, 95%CI = 1.02-1.1 p = 0.002), interobserver congruence on preoperative and TURBT findings (p < 0.001, OR = 99.3, 95%CI = 10.9-903.9), and tumor size (OR = 1.9, 95%CI = 1.33-2.71, p < 0.001) were significant predictors for malignancy. Conclusion: Direct TURBT may not be obligatory for all patients with suspicious bladder lesions. Our findings highlight the importance of a thorough preoperative diagnostic setup to avoid unnecessary procedures and spare the burden for patients. There is a need to establish more selective criteria for TURBT. (© 2026 Leitsmann, Reese, Zigeuner, Zurl, Pohl, Mischinger, Simunovic, Ketterer, Koll, Mannweiler, Leitsmann and Ahyai.) |
| Competing Interests: | The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author ML declared that they were an editorial board member of Frontiers at the time of submission. This had no impact on the peer review process and the final decision. |
| References: | Dtsch Arztebl Int. 2024 May 3;121(9):300-301. (PMID: 38934070) BJU Int. 2023 Jun;131(6):712-719. (PMID: 36251366) Histopathology. 2022 Oct;81(4):459-466. (PMID: 35502823) Int J Urol. 1995 Jun;2 Suppl 2:8-22. (PMID: 7553309) Ann Surg. 2004 Aug;240(2):205-13. (PMID: 15273542) Cancer Treat Res Commun. 2021;27:100369. (PMID: 33838570) J Urol. 2003 Aug;170(2 Pt 1):438-41. (PMID: 12853794) Cancers (Basel). 2021 Aug 30;13(17):. (PMID: 34503188) Can Urol Assoc J. 2009 Apr;3(2):131-5. (PMID: 19424467) J Telemed Telecare. 2018 Oct;24(9):603-607. (PMID: 28920525) Urol Pract. 2015 Sep;2(5):260-264. (PMID: 37559306) BJU Int. 2012 Jun;109(11):1666-73. (PMID: 22044434) Eur Urol. 2019 Jul;76(1):57-58. (PMID: 31000355) J Endourol. 2023 Jul 11;:. (PMID: 37432899) Eur Urol Oncol. 2021 Dec;4(6):927-942. (PMID: 34753702) J Endourol. 2005 Sep;19(7):861-4. (PMID: 16190845) BJU Int. 2016 May;117(5):783-6. (PMID: 26435378) |
| Contributed Indexing: | Keywords: TURBT; bladder cancer; diagnostic setup; malignancy; overtreatment; predictive parameters |
| Entry Date(s): | Date Created: 20260629 Date Completed: 20260629 Latest Revision: 20260813 |
| Update Code: | 20260814 |
| PubMed Central ID: | PMC13303723 |
| DOI: | 10.3389/fsurg.2026.1813017 |
| PMID: | 42369638 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2296-875X |
|---|---|
| DOI: | 10.3389/fsurg.2026.1813017 |